0W4N.LSE Formycon AG
- Market cap
- EUR 150M
- P/E
- -
- P/B
- -
- ROE
- -15.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0W4N.LSE undervalued?
Graham numberThe Graham number of Formycon AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Formycon AG fundamental analysis
No fundamental analysis for Formycon AG yet.
Formycon AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes u…
Full company profileFormycon AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Formycon AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 19.5M | 29.0M | 43.0M | 33.2M | 34.2M | 36.6M | 42.5M | 77.7M | 69.7M | 44.5M | 103M |
| Gross Profit | -1.67M | 1.14M | 9.89M | 962K | -2.19M | 10.1M | 12.1M | 23.3M | 14.8M | 3.58M | -12.2M |
| Operating Income | -1.67M | 1.14M | 7.12M | -2.27M | -5.74M | -13.8M | -17.7M | -369K | -23.0M | -29.4M | -69.4M |
| EBITDA | -3.37M | -752K | 8.04M | -1.39M | -4.92M | -12.4M | 51.5M | -214K | -118M | -2.44M | -19.9M |
| Net Income | -4.07M | -1.58M | 7.10M | -2.29M | -5.93M | -13.3M | 36.0M | 75.8M | -126M | -64.7M | -58.5M |
| EPS | -0.45 | -0.17 | 0.75 | -0.23 | -0.54 | -1.20 | 2.59 | 4.72 | -7.18 | -3.66 | -3.31 |
| Balance Sheet | |||||||||||
| Total Assets | 25.2M | 30.8M | 39.6M | 53.6M | 75.6M | 70.7M | 854M | 890M | 772M | 740M | 714M |
| Total Liabilities | 4.29M | 5.28M | 6.38M | 5.34M | 7.56M | 14.8M | 497M | 388M | 310M | 340M | 328M |
| Shareholders' Equity | 20.9M | 25.5M | 33.2M | 48.2M | 68.0M | 55.9M | 357M | 503M | 462M | 399M | 386M |
| Cash & Short-term Investments | 14.0M | 15.5M | 12.3M | 22.4M | 42.2M | 25.2M | 9.82M | 27.0M | 41.8M | 68.8M | 51.8M |
| Total Debt | - | 789.85 | - | - | 4.98M | 5.28M | 49.3M | 29.5M | 10.6M | 9.56M | 8.52M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.03M | -4.21M | 13.3M | -1.51M | -5.21M | -13.5M | -19.0M | -9.40M | -23.0M | 11.5M | - |
| Capital Expenditure | 1.33M | 432K | 1.07M | 1.01M | 650K | 941K | 26.8M | 1.03M | 1.55M | 737K | 334K |
| Free Cash Flow | -6.36M | -4.64M | 12.2M | -2.52M | -5.86M | -14.5M | -45.8M | -10.9M | -24.5M | 10.8M | - |
| Ratios | |||||||||||
| ROE | -19.5% | -6.2% | 21.4% | -4.8% | -8.7% | -23.8% | 10.1% | 15.1% | -27.2% | -16.2% | -15.2% |
| ROA | -16.1% | -5.1% | 17.9% | -4.3% | -7.8% | -18.8% | 4.2% | 8.5% | -16.3% | -8.7% | -8.2% |
| Net Profit Margin | -20.8% | -5.5% | 16.5% | -6.9% | -17.3% | -36.3% | 84.7% | 97.6% | -180.4% | -145.5% | -56.8% |
| Debt to Equity | - | 0.00x | - | - | 0.07x | 0.09x | 0.14x | 0.06x | 0.02x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Formycon AG dividends
Formycon AG has not paid dividends in the last 9 fiscal years.
Who owns Formycon AG
- Insiders 30.41%
- Institutions 31.28%
- Public & others 38.31%
- Shares outstanding 9.34M
- Free float 13.4M
Formycon AG company profile
- Company name
- Formycon AG
- Ticker
- 0W4N.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 196
- Fiscal year end
- December
- Address
- Fraunhoferstrasse 15, Planegg, Germany, 82152
- Phone
- 49 89 864 667 100
- Website
- formycon.com
About Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, asthma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, sinusitis with nasal polyps area, other tumor and genetic diseases; and FYB208 and FYB209 that is indicated for immunology areas. Formycon AG has cooperation agreements with Biocelys S.A. and Santo Biosimilar GmbH in connection with a biosimilar candidate. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Formycon AG management
6- Dr. Stefan GlombitzaCEO, COO & Chair of the Executive Board · born 1965
- Dr. Nicolas Combe Ph.D.Co-Founder
- Mr. Enno SpillnerCFO & Member of the Executive Board · born 1970
- Dr. Andreas SeidlChief Scientific Officer & Member of the Executive Board · born 1969
- Ms. Nicola MikulcikChief Business Officer & Member of the Executive Board · born 1971
- Dr. Friedrich-Wilhelm SteinwegCo-Founder